The report “Global Enzyme Replacement Therapy Market, By Enzyme Type (Agalsidase Beta, Velaglucerase Alfa, Imiglucerase, Taliglucerase, Alglucosidase, Alfa, Laronidase, Idursulfase, Galsulfase, Pegademase, and Others), By Indication (Fabry Disease, Gaucher Disease, Pompe Disease, Scheie Syndrome, Hunter Disease, Maroteaux-Lamy Syndrome, and Others), By End User ( Hospitals, Clinics, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Trends, Analysis and Forecast till 2030”
Key Highlights:
• In 2021, The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Sanofi SA's SNY avalglucosidase alfa for Pompe disease.
• In 2019, Global biopharmaceutical company Takeda announced the launch of the enzyme replacement therapy for 'lysosomal storage disorders' (LSDs), in an attempt to expand its portfolio of rare disease therapies in India.
Analyst View:
Rising awareness and an expanding number of market players wandering into vagrant sickness the board are key components impelling the market development. Vagrant medications that are utilized to treat these infections are expected to thrive during the estimate time frame attributable to the rising number of players putting resources into R&D to treat these uncommon sicknesses.
https://www.prophecymarketinsights.com/market_insight/Global-Enzyme-Replacement-Therapy-Market-34
Key Market Insights from the report:
The Global Enzyme Replacement Therapy Market accounted for US$ 8.24 billion in 2020 and is estimated to be US$ 16.94 billion by 2030 and is anticipated to register a CAGR of 7.50%. The Global Enzyme Replacement Therapy Market has been segmented on the basis of enzyme type, indication, end-user, and region.
• By Enzyme Type, the Global Enzyme Replacement Therapy Market is segmented into Agalsidase Beta, Velaglucerase Alfa, Imiglucerase, Taliglucerase, Alglucosidase Alfa, Laronidase, Idursulfase, Galsulfase, Pegademase, and Others.
• By Indication, the Global Enzyme Replacement Therapy Market is segmented into Fabry Disease, Gaucher Disease, Pompe Disease, Scheie Syndrome, Hunter Disease, Maroteaux-Lamy Syndrome, and Others.
• By End-User, the Global Enzyme Replacement Therapy Market is segmented into Hospitals, Clinics and Home care setting.
• By region, the Global Enzyme Replacement Therapy Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Competitive Landscape:
Key players operating in the global market of enzyme replacement therapy include Shire plc, Amicus Therapeutics, Genzyme Corporation, Pfizer Inc., BioMarin Pharmaceutical, Inc., Sigma-Tau Pharmaceuticals, Inc., Essential Pharmaceuticals Limited, Merck KGa, and AbbVie Inc.
The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.
Contact Us:
Sales
Prophecy Market Insights
1 860 531 2701
Email- [email protected]